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The androgen receptor (AR) is a member of the nuclear receptor superfamily, and is important for both male and female reproductive
health. The receptor is a target for a number of post-translational modifications including phosphorylation, which has been intensively
studied in vitro. However, little is known about the phosphorylation status of the receptor in target tissues in vivo. The commonmarmoset
is a useful model for studying human reproductive functions, and comparison of the AR primary sequence from this primate shows high
conservation of serines known to be phosphorylated in the human receptor and corresponding flanking amino acids. We have used a
panel of phosphospecific antibodies to study AR phosphorylation in the marmoset ovary throughout the follicular phase and after
treatment with GNRH antagonist or testosterone propionate. In normal follicular phase ovaries, total AR (both phosphorylated and
non-phosphorylated forms) immunopositive staining was observed in several cell types including granulosa cells of developing follicles,
theca cells and endothelial cells lining blood vessels. Receptor phosphorylation at serines 81, 308, and 650 was detected primarily in the
granulosa cells of developing follicles, surface epithelium, and vessel endothelial cells. Testosterone treatment lead to a modest increase
in AR staining in all stages of follicle studied, while GNRH antagonist had no effect. Neither treatment significantly altered the pattern of
phosphorylation compared to the control group. These results demonstrate that phosphorylation of the AR occurs, at a subset of serine
residues, in a reproductive target tissue in vivo, which appears refractory to hormonal manipulations.
Reproduction (2010) 140 93–104Introduction
The androgen receptor (AR) is a member of the nuclear
receptor superfamily and mediates the action of the sex
steroids testosterone and dihydrotestosterone (Gelmann
2002, McEwan 2004). The AR is expressed in reproduc-
tive tissues of both males and females, and is known to
play important roles in fertility. However, regulation of
AR function and the identity of target genes for the
receptor in different tissues are less well understood.
Folliculogenesis involves the formation of a multi-cell
layer of granulosa cells surrounding the oocyte, which in
turn are surrounded by a theca cell layer. The theca cells
are responsible for the biosynthesis of androgens, which
can be converted to estrogens by the aromatase enzyme
that is expressed in granulosa cells in response to FSH
stimulation (Fauser & Van Heusden 1997, Hillier 2001,
Jamnongjit & Hammes 2006). Androgenic steroids play
important roles in follicle growth and survival asq 2010 Society for Reproduction and Fertility
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distribution, and reproduction in any medium, provided the original work is properlyprecursors for estrogen biosynthesis and directly through
binding to and activation of the AR. The AR has been
shown to induce expression of the genes for insulin-like
growth factor 1 (IGF1), IGF1 receptor, and FSH receptor,
and to augment growth differentiation factor 9 and FSH
signaling in granulosa cells (Weil et al. 1999, Hickey
et al. 2005, Walters et al. 2007, Lenie & Smitz 2009).
Expression of both mRNA and protein for the AR in
granulosa cells of the developing follicles has been
described in the ovaries from both human (Horie et al.
1992, Chadha et al. 1994, Rice et al. 2007) and a
number of non-human primates including rhesus
monkey (Weil et al. 1998, Chaffin et al. 1999), baboon
(Hild-Petito & Fazleabas 1997), and the common
marmoset, Callithrix jacchus (Hillier et al. 1997,
Saunders et al. 2000). AR expression has also been
observed and studied in ovaries from mouse (Kimura
et al. 2007), rat (Tetsuka et al. 1995, Tetsuka & Hillier
1996), and sheep (Juengel et al. 2006). In these diverseDOI: 10.1530/REP-10-0140
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94 I J McEwan and othersstudies, the consensus findings are that AR protein levels
change during follicle development, with the highest
levels seen in primary to tertiary stage follicles.
Significantly, three complete AR knockout (ARKO)
mouse models resulted in reduced fertility in female
animals due to defects in folliculogenesis (Yeh et al. 2002,
Hu et al. 2004, Shiina et al. 2006, Walters et al. 2007).
The AR is subject to a range of post-translational
modifications, including phosphorylation on serine
(van Laar et al. 1991, Gioeli et al. 2002, Lin et al.
2002, Ponguta et al. 2008) and tyrosine (Mahajan et al.
2007) residues, and acetylation (Fu et al. 2002, Gaughan
et al. 2002), and sumoylation (Poukka et al. 2000,
Callewaert et al. 2004) on lysine residues. Up to 11
phosphorylated serine and 1 tyrosine residues have been
identified to date in cell culture systems after different
hormonal or growth factor stimulations (van Laar et al.
1991, Gioeli et al. 2002, Lin et al. 2002, Mahajan et al.
2007, Ponguta et al. 2008). Phosphorylation of the
receptor protein represents a potentially powerful means
of regulating receptor levels and function, without the
requirement for de novo synthesis. However, little is
known about the phosphorylation status of the AR in
normal target tissues in vivo. Recently, a number of
phosphoserine-specific antibodies have been described
for the AR (Black et al. 2004, Taneja et al. 2005, Yang
et al. 2005, Ponguta et al. 2008), and the availability of
these tools provides the possibility of screening archival
tissue samples for cell-specific or developmental
changes in receptor phosphorylation, which will be
important for a fuller understanding of the role of this
chemical modification.
Of the commonly used non-human primate models in
reproduction research, the marmoset, C. jacchus, has
particular advantages with respect to the study of ovarian
folliculogenesis. First, marmosets normally ovulate three
follicles per cycle (range 1–4) that reach up to 4 mm in
diameter so that during the mid-late follicular phase, the
ovaries contain a wealth of follicles at different stages of
development (Gilchrist et al. 2001). Also, the presence of
follicular tissue is emphasized because prostaglandin-
induced structural luteolysis leads to removal of luteal
tissue. Marmoset ovaries, weighing around 150 mg, are
ideal to study, being easily accommodated on a
microscope slide, so that in ovaries of the mid- and late
follicular phase, numerous follicles at different stages of
development can be compared within each section.
Furthermore, in our laboratory, a number of studies have
been performed in which follicular development has
been influenced by inhibition of GNRH (Taylor et al.
2004, 2007), allowing the secondary effects of this
treatment to be investigated (Thomas et al. 2007). In
the present study, we have addressed the question of
changes in and regulation of AR phosphorylation at
different stages of development in the marmoset ovary at
the normal follicular phase and after manipulation
of testosterone levels by suppressing ovarian sexReproduction (2010) 140 93–104steroid secretion by GNRH antagonist treatment or
by increasing exposure to testosterone by administration
of testosterone propionate in vivo as described in the
rhesus macaque (Vendola et al. 1999). By employing
immunohistochemical localization using a panel of
three phosphoserine-specific antibodies, as well as
antibodies recognizing total levels of receptor, we have
investigated for the first time the phosphorylation of the
AR in the primate ovary.Results
Eleven phosphorylated serine residues have been
identified which are distributed throughout the length
of the AR (Fig. 1A; van Laar et al. 1991, Gioeli et al.
2002, Lin et al. 2002, Ponguta et al. 2008). In order to
determine whether receptor phosphorylation occurs in
vivo in a target tissue, a panel of antibodies recognizing
phosphorylated serines 81, 308, and 650 were used on
marmoset ovarian tissue sections. The predicted marmo-
set AR is 887 amino acids in length and has a theoretical
molecular mass of 95 659 kDa. Analysis of the primary
amino acid sequence for the marmoset AR revealed
strong conservation of serines corresponding to residues
in the human AR at positions 81, 94, 308, and 650,
which are known to be phosphorylated in the human
receptor (Jenster et al. 1994, Zhou et al. 1995, Blok et al.
1998, Lin et al. 2001, Zhu et al. 2001, Gioeli et al. 2002,
Rigas et al. 2003, Black et al. 2004, Wong et al.
2004, Chen et al. 2006, Kesler et al. 2007, Yang et al.
2007, Zong et al. 2007, Ponguta et al. 2008; Fig. 1B). In
addition, there was high conservation of flanking amino
acids especially a proline at positions 82, 95, 309, and
651 immediately C-terminal of the phosphorylated
serine (Fig. 1B). In contrast, the mouse and rat ARs
have changes in flanking amino acids, which may impair
phosphorylation or detection with phospho-specific
antibodies raised against the human sequence. Indeed,
none of the phospho-specific antibodies tested
appeared to cross-react with the mouse or rat AR in
immunohistochemistry (data not shown). Figure 1C
shows a western blot of marmoset ovarian tissue extract
probed with an antibody against the N-terminus (N20) of
the receptor that recognizes both phosphorylated and
non-phosphorylated forms of the receptor. The marmoset
AR migrated a little slower than the 98 kDa marker.
After immunoprecipitation (IP) of the AR, with an
antibody against the C-terminal domain (C19), but not
a control IgG, forms of the receptor phosphorylated
on serines 81, 308, and 650 were detected (Fig. 1D),
indicating post-translational modification of the receptor
in the primate ovary.
Morphological description of control and GNRH
antagonist-treated ovaries has been reported previously
(Taylor et al. 2004). Briefly, all classes of developing
follicles up to the stage of dominant follicles werewww.reproduction-online.org
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Figure 1 Comparison of primary amino acid
sequence of the human, marmoset, and rodent
AR. (A) Schematic representation of the human
androgen receptor (AR) showing the domain
organization and the position of 11 phosphory-
lated serine residues. The residues analyzed in the
present study are highlighted in yellow. LBD,
ligand-binding domain; DBD, DNA-binding
domain; AF1, activation function 1.
(B) Comparison of the primary amino acid
sequence of the human, marmoset, rat, and
mouse AR. Only partial amino acid sequence is
shown for fourphosphorylated serine residues (P).
(C) Western blot analysis of total AR (N20
antibody detecting both non-phosphorylatedC
phosphorylated forms) in a protein extract of the
marmoset ovary. M, molecular weight marker.
(D) The AR was immunoprecipitated using
antibody C19 (against the AR-LBD) and the
membranes probed with the phospho-specific
antibodies (against phosphoserines 81, 308,
and 650). IgG represents a control immuno-
precipitation using a non-receptor-specific
antibody as a control. IP, immunoprecipitation;
WB, western blot.
Phosphorylation of the AR in vivo 95present in all three groups, while the latter class was
present in the day 10 controls only (2–4 per animal).
As anticipated, treatment with testosterone propionate
was also associated with the presence of large numbers
of antral follicles and the absence or reduction in
numbers of dominant follicles. In order to determine
the location of the phosphorylated AR in the ovary,
immunohistochemistry was undertaken on whole tissue
sections. Examination of ovaries at the two control stages
of the cycle revealed a similar intensity of staining within
each class of follicle, irrespective of stage. Because
healthy tertiary follicles were most abundant in the day 5www.reproduction-online.orgovaries, these were selected for semi-quantitative
analysis and only pre-ovulatory follicles from the day
10 controls were scored. As reported previously (Hillier
et al. 1997, Saunders et al. 2000), in the ovaries of
control marmosets, AR-positive nuclear staining was
observed in the granulosa cells at all stages of follicle
development when sections were incubated with an
antibody directed against the N-terminus of the mature
protein (Fig. 2A N20). AR-positive staining in granulosa
cells increased as follicles developed (Fig. 2A panels a
and d and B), and began to decrease during early and
late atresia (data not shown). The theca cell layer, stroma,Reproduction (2010) 140 93–104
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Figure 2 AR expression in the marmoset ovary.
(A) Immunohistochemistry staining for total AR
using an antibody against the first 20 amino acids
(N20). Panels a and d, control group; panels b
and e, after treatment with testosterone propio-
nate; and panels c and f, after treatment with
GNRH antagonist. Panels a–c and d–f represent
!10 and!20 magnification respectively; size
barZ100 mm. 18, 28, and 38 examples of primary,
secondary, and tertiary follicles are shown; OSE,
ovarian surface epithelium. (B) Scoring for the
relative strength of staining for total AR in control
animals (day 5); after treatment with GNRH
antagonist on day 0; and after treatment with
testosterone propionate on day 0. Ovaries from
four animals were analyzed for each condition,
and scoring was done as detailed in Materials
and Methods. Briefly, only primary/transitional
and secondary follicles with a clearly visible
oocyte were scored as follows: 0, no detectable
staining; 1C, 2C, and 3C, weak, moderate, and
strong staining respectively. The percentage of
granulosa cells at each intensity for primary,
secondary, and tertiary follicles has been plotted
together with the percentage of OSE.
96 I J McEwan and othersand regions of the ovarian surface epithelium (OSE) also
all stained positive for AR (Fig. 2A panels a and d).
Treatment with testosterone propionate resulted in
strong staining for total AR in primary follicles through to
tertiary follicles and the OSE (Fig. 2A panels b and e and B).
From the semi-quantitative scoring of the AR staining, it
could be seen that there was an overall increase in the
levels of receptor at all stages of follicle growth,
especially primary and secondary follicles (Fig. 2B).
To investigate the effect of GNRH antagonist treatment
on AR phosphorylation, ovarian sections from animals
treated on day 0 were stained for total AR or selected
phosphoserine modifications. After GNRH antagonist
treatment, AR staining was observed in all stages of
follicle present, and again predominantly in granulosa
and theca cells of primary, secondary, and tertiary
follicles and reduced in atretic follicles (Fig. 2A panels c
and f and B). This treatment results in failure of emergence
of dominant follicles (Taylor et al. 2004).
Phosphorylated forms of the AR were similarly
observed at all stages of follicle growth. The pattern ofReproduction (2010) 140 93–104phosphorylated serine 81 essentially mirrors that of total
AR with most intense immunopositive staining seen in
the secondary and tertiary follicles and the OSE (Fig. 3A
panel a and B). Nuclear staining was also detected in the
theca cell layer.
Phosphorylation on serine 308, also present in the
AR-amino terminal domain (NTD), was restricted mainly
to the granulosa cells of secondary and tertiary follicles
with little or no staining of primary (Fig. 4A panel a and B)
or pre-ovulatory follicles (data not shown). Phosphoryl-
ation of serine 308 was also more punctate, with some
strongly staining granulosa cells (Fig. 4).
The pattern of phosphorylation of serine 650, located
within the hinge domain, was observed in all stages of follicle
development from primary onwards, with the most intense
staining seen in secondary and tertiary follicles (Fig. 5A panel
a and B). Immunopositive staining was reduced, but
still observable in pre-ovulatory/dominant follicles and
reduced or absent in atretic follicles (data not shown).
Staining for total AR and phosphoserines 81 and 650
was also observed in regions of the OSE, while stainingwww.reproduction-online.org
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Figure 3 Detection of AR phosphorylated on
serine 81. (A) Immunohistochemistry staining
for AR using an antibody against phosphoserine
81 (pSer81). Panel a, control animal (day 5);
panel b, after treatment with testosterone
propionate; and panel c, after treatment with
GNRH antagonist. Panels a–c represent !20
magnification; size barZ100 mm. 18, 28, and 38
examples of primary, secondary, and tertiary
follicles are shown; OSE, ovarian surface
epithelium. (B) Scoring for the relative strength
of staining for total AR in control animals (day 5);
after treatment with GNRH antagonist on day 0;
and after treatment with testosterone propionate
on day 0. Ovaries from four animals were
analyzed for each condition, and scoring was
done as detailed in Materials and Methods.
Briefly, only primary/transitional and secondary
follicles with a clearly visible oocyte were
scored as follows: 0, no detectable staining; 1C,
2C, and 3C, weak, moderate, and strong
staining respectively. The percentage of
granulosa cells at each intensity for primary,
secondary, and tertiary follicles has been plotted
together with the percentage of OSE.
Phosphorylation of the AR in vivo 97for phosphoserine 308 was more patchy with only some
cells staining positive (Figs 2–5). It is also noteworthy that
positive staining for total and phosphorylated forms of
the AR was also observed in about 30% of endothelial
cells lining blood vessel walls (Fig. 6). Taken together, the
data indicate that the AR phosphorylated on specific
serine residues is detectable in cells of the primate ovary.
As a control for staining specificity of the anti-
phosphoserines 81, 308, and 650 antibodies, positive
staining was efficiently competed with the respective
phosphoserine peptide (Fig. 7 panels a–f). AR-positive
immunostaining using the N20 antibody was not
significantly impaired in the presence of these peptides
(Fig. 7 panel h and data not shown).
The phosphorylation of the AR on serines 81, 308, and
650 was not significantly altered by manipulating the
hormonal environment (Figs 3–5); thus, antagonizing
GNRH action or raising testosterone levels cause
morphological changes in the primate ovary, but had
little impact on the phosphorylation status of the AR.
Overall AR phosphorylation on serines 81, 308, and 650
was detected in several cell types of the primate ovary,
most notably the granulosa cells of developing follicles
and in regions of the OSE, together with theca and
stromal cells and a proportion of endothelial cells lining
blood vessels.www.reproduction-online.orgDiscussion
The marmoset model has proved useful in understanding
primate ovarian biology and has the advantage that
extensive studies have been carried out on manipulating
the hormone environment in vivo. In this study, we have
confirmed and extended previous work reporting AR
expression in the primate ovary. Nuclear immuno-
positive staining of total AR was observed strongly in
the granulosa cells, but also in the OSE, theca cell layer
and stroma cells, and in a proportion of endothelial cells
lining blood vessels. These findings are in good
agreement with earlier work describing the similar
expression patterns of the AR mRNA and/or protein in
the rhesus monkey, marmoset, and human ovary
(Chadha et al. 1994, Hillier et al. 1997, Weil et al.
1998, Saunders et al. 2000). Significantly, we show that
phosphorylated forms of the AR are present primarily in
granulosa cells, but also in other cell types including the
OSE and endothelial cells.
In addition to their presence in the hormone-
producing cells of the follicle, the presence of AR and
its phosphorylated forms in the OSE and a subset of
ovarian endothelial cells indicate that ovarian blood
vessels and OSE may be a target for androgen action. AR
has been localized in endothelial cells in a number of
tissues (Pelletier et al. 2000, Gonzales et al. 2007), but itsReproduction (2010) 140 93–104
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Figure 4 Detection of AR phosphorylated on
serine 308. (A) Immunohistochemistry staining
for AR using an antibody against phosphoserine
308 (pSer308). Panel a, control animal (day 5);
panel b, after treatment with testosterone
propionate; and panel c, after treatment with
GNRH antagonist. Panels a–c represent !20
magnification; size barZ100 mm. 18, 28, and 38
examples of primary, secondary, and tertiary
follicles are shown; OSE, ovarian surface
epithelium. Open arrow head represents an
example of a strongly staining cell. (B) Scoring
for the relative strength of staining for total AR in
control animals (day 5); after treatment with
GNRH antagonist on day 0; and after treatment
with testosterone propionate on day 0. Ovaries
from four animals were analyzed for each
condition, and scoring was done as detailed in
Materials and methods. Briefly, only primary/
transitional and secondary follicles with a
clearly visible oocyte were scored as follows: 0,
no detectable staining; 1C, 2C, and 3C, weak,
moderate, and strong staining respectively.
The percentage of granulosa cells at each
intensity for primary, secondary, and tertiary
follicles has been plotted together with the
percentage of OSE.
98 I J McEwan and othersrole in influencing vascular development and function is
unclear. Several other factors have been shown to have
major actions on these cells (Fraser & Duncan 2009), and
it is likely that these potential sites of action are of
much less significance than the role of androgen on
the granulosa cells. Several studies have observed the
expression of the AR in the OSE and the epithelial cells of
inclusions cysts (see Saunders et al. 2000, Edmondson
et al. 2002). Also androgen stimulation of primary
cultures of human OSE cells increased cell proliferation
(Edmondson et al. 2002), suggesting that the OSE is an
androgen target.
In cell culture systems, phosphorylation of serines 81,
308, and 650 has been shown to be induced by
androgen treatment (see Gioeli et al. 2002). Further-
more, a number of kinases capable of phosphorylating
these residues have been identified in vitro. In the case
of phosphorylation of serines 81 and 308, the cell
cycle-dependent kinases 1 and 11 have been implicated
(Chen et al. 2006, Zong et al. 2007). Phosphorylation of
serine 308 has been associated with repression of AR
activity by cyclin D3/CDK11 (Zong et al. 2007).
Furthermore, targeting the receptor to the cytoplasmic
or nuclear compartments resulted in a bias of nuclear
phosphorylation of serines 81 and 308 (Kesler et al.
2007), which the authors suggest plays a role in
nucleocytoplasmic shuttling. However, earlier studiesReproduction (2010) 140 93–104failed to see a role for serine 81 phosphorylation in
transactivation assays (Jenster et al. 1994, Zhou et al.
1995) or nuclear/cytoplasmic distribution (Jenster et al.
1994). Consistent with a lack of effect directly on
transactivation, Paschal and co-workers (Black et al.
2004) reported that serine 81 phosphorylation occurs
subsequent to receptor–co-regulatory protein inter-
actions. In the absence of an unambiguous role for
phosphorylation of the individual serines at positions 81
and 308, it is tempting to speculate that what matters
is the net phosphorylation of the receptor rather than
modification of individual residues. Alternatively, it is
conceivable that the functional consequences of phos-
phorylating individual serines maybe cell and/or gene
specific. Further work will be necessary to distinguish
these possibilities.
Serine 650 can be phosphorylated in vitro by protein
kinase A and protein kinase C and by members of the
MAPK family, including the stress-induced kinases p38a
and JNK (Gioeli et al. 2002, 2006). Although phos-
phorylation of this residue is well documented, the
functional consequences of this modification remain a
subject of debate. Initial studies reported a modest
impairment of transactivation when the serine is mutated
to alanine (S650A; Zhou et al. 1995), and the
functionally similar mutation to glycine (S650G) is
associated with mild androgen insensitivity syndromewww.reproduction-online.org
Control Testosterone GNRH antagonistA
a b c
pSer650
0
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
AR
 p
os
itiv
e
 n
u
cl
ei
 (p
Se
r65
0)
Pr
im
ar
y
Ea
rly
 s
ec
on
da
ry
La
te
 s
ec
on
da
ry
Te
rti
ar
y
O
SE
Pr
im
ar
y
Ea
rly
 s
ec
on
da
ry
La
te
 s
ec
on
da
ry
Te
rti
ar
y
O
SE
Pr
im
ar
y
Ea
rly
 s
ec
on
da
ry
La
te
 s
ec
on
da
ry
Te
rti
ar
y
O
SE
1+ 2+ 3+
GNRH antagonistTestosteroneControl
B
Figure 5 Detection of AR phosphorylated on
serine 650. (A) Immunohistochemistry staining
for AR using an antibody against phosphoserine
650 (pSer650). Panel a, control animal (day 5);
panel b, after treatment with testosterone
propionate; and panel c, after treatment with
GNRH antagonist. Panels a–c represent !20
magnification; size barZ100 mm. 18, 28, and 38
examples of primary, secondary, and tertiary
follicles are shown; OSE, ovarian surface
epithelium. Open arrow head represents an
example of a strongly staining cell. (B) Scoring
for the relative strength of staining for total AR in
control animals (day 5); after treatment with
GNRH antagonist on day 0; and after treatment
with testosterone propionate on day 0. Ovaries
from four animals were analyzed for each
condition, and scoring was done as detailed in
Materials and methods. Briefly, only primary/
transitional and secondary follicles with a
clearly visible oocyte were scored as follows: 0,
no detectable staining; 1C, 2C, and 3C, weak,
moderate, and strong staining respectively.
The percentage of granulosa cell at each
intensity for primary, secondary, and tertiary
follicles has been plotted together with the
percentage of OSE.
Phosphorylation of the AR in vivo 99(Ferlin et al. 2006) and male infertility (Zuccarello et al.
2008). On the other hand, others have found no major
changes in protein–protein interactions or transactiva-
tion activity with the same mutation (Wong et al. 2004).
More recently, Gioeli et al. (2006) have demonstrated
that serine 650 phosphorylation regulates nuclear
export, with the non-phosphorylatable S650A mutant
receptor retained in the nucleus and a concomitant
increase in a target gene expression. Similarly, Chen
et al. (2009) reported that serine 650 phosphorylation
was a target for protein phosphatase 1, and it was
involved in nuclear export and subsequent receptor
turnover. However strikingly, in the present study,
immunodetection of phosphoserines 81, 308, and 650
in vivo appeared predominantly nuclear, although some
cytoplasmic staining was also observed.
The gonadotropins FSH and LH play critical roles in
folliculogenesis, theca and granulosa cell functions, and
ovulation, including the LH-stimulated activation of
androgen biosynthesis in theca cells (Fauser & Van
Heusden 1997, Hillier 2001, Jamnongjit & Hammes
2006). The release of these peptide hormones from the
pituitary is in turn regulated by GNRH. Treatment of
animals with a GNRH antagonist on day 0 of the
ovulatory cycle results in inhibition of development of
large dominant follicles and suppression of ovarian sex
hormone secretion (Taylor et al. 2004). The likelywww.reproduction-online.orgdeprivation of the follicles of intra-ovarian androgen
might have been expected to result in decreased
expression of the AR and impact directly on AR
phosphorylation. Conversely, treatment with testosterone
propionate throughout the follicular phase might
have been expected to increase expression and
phosphorylation. An increase in AR in the testosterone
propionate ovaries was confirmed; however, our semi-
quantitative scoring did not reveal substantive changes
in any other parameters following these treatments.
This indicates that AR phosphorylation in ovarian
compartments is not closely regulated by testosterone,
at least over the 10-day period of the present study.
Interestingly, an increase in receptor mRNA has been
observed in the granulosa cells in the rhesus monkey
after testosterone treatment and was correlated with cell
proliferation (Weil et al. 1998). Although phosphory-
lation on serines 81, 308, and 650 is refractory to
hormone manipulation in vivo, it does not necessarily
follow that phosphorylation plays no role in receptor
function in the primate ovary, and this is an area of
ongoing investigation.
To date, phosphorylation of the AR has been studied
almost exclusively in cell culture-based systems with
exogenously expressed receptor or in the bone-derived
metastatic prostate cancer cell line LNCaP, containing a
mutant AR. In the present study, we have uniquelyReproduction (2010) 140 93–104
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Figure 6 Total AR and phosphorylated forms in
endothelial cells. Detection of total AR (N20)
and phosphorylated forms (serines 81, 308, and
650) in a proportion of endothelial cells (/)
lining blood vessels. Staining is of an ovary from
a control animal.
100 I J McEwan and othersdemonstrated in vivo phosphorylation of the AR in a
reproductive tissue. These findings complement and
expand upon work describing the presence of phos-
phorylated serine 213 in the developing and adult
prostate gland (Taneja et al. 2005) and in clinical
samples of prostate cancer (McCall et al. 2008). Taken
together with the present study, these data indicate that
phosphorylation of the AR has the potential to regulate
receptor function in male and female reproductive
tissues and in disease.Materials and Methods
Antibodies
Total AR protein expression was detected using a rabbit
polyclonal antibody (N20, sc-816) raised against the receptor
N-terminus (Santa Cruz Biotechnology Inc., Santa Cruz, CA,
USA). Antibodies recognizing phosphoserines 81 (Millipore
Ltd (UK), Watford, UK), 308 (sc26406-R; Santa Cruz
Biotechnology Inc.), and 650 (ab47563; Abcam, Cambridge,
UK) were all rabbit polyclonals raised against phosphoserine-
containing peptides derived from the human AR sequence.Animals, treatments and tissue collection
As the objective was to determine changes in receptor
localization during follicular development, control ovaries
were examined at two stages of the follicular phase of the
ovulatory cycle. To synchronize the timing of events during
the cycle, adult female marmosets were injected with 1 mg
prostaglandin PGF2a analog (cloprostenol, Planate; Coopers
Animal Health Ltd, Crewe, UK), i.m. on day 13–15 of the luteal
phase to induce luteolysis. The day of prostaglandin injection
was designated as follicular day 0. This method of synchroniz-
ing follicular recruitment was followed by follicle selection on
day 5 and ovulation between day 9 and 11. Thus, ovaries were
studied on day 5 as they contained an abundance of healthyReproduction (2010) 140 93–104tertiary follicles and on day 10 of the cycle when pre-ovulatory
follicles were present. To study the effects of sex hormone
ablation on the one hand and hyperstimulation with testoster-
one on the other hand, marmosets (nZ4 per group) were
injected with PGF2a analog as the controls, but were treated
on day 0 with either a GNRH antagonist, Teverelix
[N-Ac-D-Nal1,D-pCl-Phe2,D-Pal3,D-(Hci)6,Lys(iPr)8,D-Ala10]
GNRH (Europeptides, Argenteuil, France), 12 mg/kg, s.c., to
block gonadotropin secretion (Taylor et al. 2004), or testoster-
one propionate (AMS Biotechnology, Abingdon, UK), 20 mg,
s.c., in 200 ml vegetable oil repeated on days, 1, 3, 5, 7, and 9.
On day 10, animals were killed as described previously (Taylor
et al. 2004), and ovaries were collected into 4% neutral-
buffered formalin for 24 h before being transferred into 70%
ethanol, dehydrated, and embedded in paraffin according to
standard procedures. Ovaries from control and GNRH
antagonist treatments had been stored at room temperature in
paraffin blocks having been generated from previously
described experiments (Taylor et al. 2004, 2007). Treatment
with testosterone propionate was carried out in accordance
with the Animals (Scientific Procedures) Act, 1986, and
approved by the Local Ethical Review Process Committee.
Ovarian sections (5 mm) were cut onto SuperFrost slides (BDH,
Merck Co., Inc.), and stained with hematoxylin and eosin or
subjected to immunohistochemistry as described below.Marmoset androgen receptor
The coding sequence of the marmoset AR gene and conceptual
translation were determined in two stages. Initially, sequences
of human AR exons were used to blast the C. jacchus genome-
sequencing database at the Genome Sequencing Center at
Washington University Medical School, St Louis, MO, USA
(http://genome.wustl.edu). High scoring segments were
employed to download sequencing traces from the National
Center for Biotechnology Information Trace Archive, and these
were aligned using ClustalW2 (Larkin et al. 2007). Sequences
shared between three and six traces were assembled to create
contiguous regions of the gene, which were used to confirmwww.reproduction-online.org
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Figure 7 Specificity of phospho-specific antibodies.
Panels a, c, and e show staining of follicles for
phosphoserines 81, 308, and 650 respectively.
Panels b, d, and f represent staining in the
presence of competing amounts of the cognate
phosphopeptide. Panel g represents no primary
antibody. Panel h represents staining for AR with
N20 in the presence of an excess of phosphoserine
81 peptide. Magnification!10.
Phosphorylation of the AR in vivo 101intron/exon splice junctions. The coding sequence was
subsequently translated to give a predicted protein primary
sequence. Most recently, the coding sequence was confirmed by
comparison to the 6!whole-genome shotgun supercontig 3.2.Immunohistochemistry
After dewaxing and rehydration of tissue sections, antigen
retrieval was achieved in 50 mM glycine–EDTA buffer (pH 8) for
5 min in a pressure cooker. Slides were then blocked with 3%
(v/v) H2O2 in methanol for 30 min, and washed with water and
then with 50 mM Tris–HCl (pH 7.4) and 150 mM NaCl (TBS).
Slides were blocked with 20% normal goat or horse serum and
5% BSA in TBS for up to 1 h prior to incubation overnight at 4 8C
with primary antibodies. Antibodies were used at the following
dilutions: N20 (1:200, 3 nM); pSerine 81 (1:50, 0.07 mM);
pSerine 308 (1:100, 0.01 mM); and pSerine 650 (1:25, 0.27 mM).
Slides were then washed twice with TBS, and incubated
with goat or horse anti-rabbit secondary antibody with
polymerized reporter enzyme staining system (EnVision; Dakowww.reproduction-online.orgCorporation, Copenhagen, Denmark; or ImmPress, Vector Labs,
Peterborough, UK) for up to 1 h at room temperature. After two
wash steps with TBS, DAB substrate was added, and the
reaction developed for 2–4 min. Images were captured using a
Provis microscope (Olympus Corp., London, UK). All ovaries
were subjected to immunohistochemistry in the same run.
Competing peptides containing phosphorylated serine
residues were custom synthesized by EZBiolab (Westfield, IN,
USA): pSerine 81 QQQQQQQETpSPRQQ; pSerine 308
KSTEDTAEYpSPFKG; and pSerine650 EEGEASSTTpSPTEE.
Peptides were added to antibody solutions at concentrations
ranging from 0.03 to 2.58 mM prior to tissue incubation.Analysis of sections
Stages of follicular development were defined as described
previously (Taylor et al. 2004, 2007), i.e. primordial (oocyte
surrounded by a few flattened granulosa cells), transitory
(oocyte surrounded by flattened granulosa cells and at least one
cuboidal granulosa cell), primary (oocyte surrounded byReproduction (2010) 140 93–104
102 I J McEwan and othersa complete layer of cuboidal cells), early secondary (two to four
granulosa cell layers, no antrum), late secondary (more than
four granulosa cell layers, no antrum), tertiary (follicles
containing an antrum), and dominant (large antral follicles,
O2 mm). Follicles were classified as healthy if they contained a
normal-shaped oocyte surrounded by granulosa cells that were
regularly apposed on an intact basement membrane with
normal appearance of granulosa cell nuclei without signs of
pycnosis. For examination of primordial to late secondary
follicles, only those with a visible oocyte containing a nucleus
were considered to ensure proper follicular classification.
Follicles were classified as atretic when more than 5% of
granulosa cells showed signs of pycnosis and detachment of
cells from the basement membrane. The numbers of follicles
analyzed were as follows: controls (transitory/primary, nZ262;
early secondary, nZ154; late secondary, nZ29; tertiary,
nZ200; dominant, nZ26; and atretic, nZ19); GNRH
antagonist-treated (transitory/primary, nZ287; early second-
ary, nZ148; late secondary, nZ48; tertiary, nZ142; dominant,
nZ0; and atretic, nZ21), and testosterone propionate-treated
(transitory/primary, nZ274; early secondary, nZ137; late
secondary, nZ36; tertiary, nZ103; dominant, nZ2; and
atretic, nZ39).
Sections were analyzed by two observers blinded to the
treatment category. The degree of staining for AR protein was
based upon a modified HSCORE. Thus, intensity of staining in
granulosa cells and OSE was classed as 1, weak; 2, moderate;
3, strong. The percentage of granulosa cells and OSE at each
intensity was then calculated. Theca and endothelial cells
were also examined.Immunoprecipitation and western blot analysis
of the marmoset AR
For IP, a single normal ovary was homogenized using RIPA
buffer (1% Triton X-100, 0.25% sodium deoxycholate, 50 mM
Tris–HCl (pH 7.4), 150 mM NaCl, and 1 mM EDTA) containing
protease inhibitors (Complete Mini protease inhibitor cocktail
(Roche) and 1 mM phenylmethylsulfonyl fluoride) and
phosphatase inhibitors (2 mM activated Na3VO4; 50 mM
NaF; 20 mM b-glycerophosphate disodium; phosphatase
inhibitor cocktail containing cantharidin, bromotetramisole,
and microcystin-LR (Sigma–Aldrich)). Protease and phospha-
tase inhibitors were added to the lysis buffer just before
homogenization. The AR was immunoprecipitated from an
aliquot of 0.5 mg protein/ml using 2.5 mg of anti-human AR
(C-19, Santa Cruz Biotechnology Inc.) and protein A affinity
resin (Sigma–Aldrich). For each IP experiment, appropriate
negative controls (rabbit IgG and rabbit serum) were conducted
simultaneously. Prior to the incubation with the C-19 antibody,
the tissue homogenate was precleared with protein A resin. The
final pellets were washed three times with Ca2C/Mg2C PBS.
Purified immune complexes associated with AR were mixed
with 2! electrophoresis sample buffer, boiled, and then
resolved by SDS-PAGE. These complexes were further
analyzed by western blotting using antibodies raised against
AR and specific serine phosphorylation sites. Briefly,
membranes were blocked with 5% non-fat dry milk/TBS
for 1 h followed by incubation with primary antibodiesReproduction (2010) 140 93–104diluted in 5% milk/TBS for 2 h at room temperature: N20
(1:100), pSerine81 (1:500), pSerine308 (1:200), and pSer-
ine650 (1:200). The secondary antibodies such as IRDye680-
conjugated affinity-purified goat anti-mouse IgG or
IRDye800CW-conjugated affinity-purified goat anti-rabbit
IgG (Li-COR Biosciences, Cambridge, UK) at 1:1000 dilution
were incubated for an hour. Fluorescence was analyzed using
the Odyssey Infrared Imaging system from LI-COR Biosciences.
To verify the specificity of AR, phosphoserine antibodies
blocking peptides and l protein phosphatase (100 U at 37 8C)
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